ALVO
Alvotech

193
Loading...
Loading...
News
all
press releases
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?
ALVO's partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.
Zacks·7h ago
News Placeholder
More News
News Placeholder
Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth
Alvotech's partnership-led strategy drives soaring biosimilar revenues, fresh approvals and a diversified pipeline across key therapies.
Zacks·5d ago
News Placeholder
ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
Alvotech trades near a 52-week low after a 38% drop in 2025, but soaring revenues and new biosimilar approvals highlight its growth path.
Zacks·14d ago
News Placeholder
Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus
KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.
Zacks·1mo ago
News Placeholder
Alvotech (ALVO) Q2 Earnings and Revenues Beat Estimates
Alvotech (ALVO) delivered earnings and revenue surprises of +153.85% and +50.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Wall Street Analysts Think Alvotech (ALVO) Could Surge 102.31%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 102.3% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·1mo ago
News Placeholder
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of -38.89% and +0.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.
Zacks·1mo ago
News Placeholder
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
XENE's wider Q2 loss highlights its push toward late-stage epilepsy, depression, and bipolar disorder studies with azetukalner.
Zacks·1mo ago
News Placeholder
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of +50.00% and +17.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago

Latest ALVO News

View

Advertisement. Remove ads.

Advertisement. Remove ads.